Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating Insys Therapeutics, Inc. ("Insys Therapeutics" or the "Company") (Nasdaq: INSY) concerning possible violations of federal securities laws.

If you purchased or otherwise acquired Insys Therapeutics shares and would like more information regarding the investigation, we encourage you to click here, or contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm's website at, or by email at

Insys revealed that "the Company will delay the release of its financial results for the fourth quarter and full year 2016. The Audit Committee of the Company's Board of Directors has been conducting an independent review of the Company's processes related to estimation of, and increases to, certain sales allowances recorded during 2016, with a potential reduction of 2015 net revenue and pre-tax income not expected to exceed $5 million, as well as extended payment terms offered to certain customers during the third quarter of 2016."

Insys also noted that it would delay filing its 2016 annual financial statements.

When this information was released to the public, the value of Insys Therapeutics stock fell, causing investors harm.

If you have any questions concerning your legal rights, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at, or email us at

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on

Copyright Business Wire 2010